Literature DB >> 8882097

Health care worker exposure to aerosolized ribavirin: biological and air monitoring.

R A Shults1, S Baron, J Decker, S D Deitchman, J D Connor.   

Abstract

Aerosolized ribavirin is administered frequently to treat severe respiratory syncytial virus infections. The drug's potential reproductive effects in occupationally exposed workers remains a concern among health care workers. In this evaluation, we measured urinary ribavirin concentrations in occupationally exposed health care workers. Ribavirin was detected in 16 of 26 (62%) post-work-shift urine samples that had been provided by nurses, and in five of 22 (23%) post-work-shift urine samples that had been provided by respiratory therapists (range, < 0.01 to 0.22 mumol/L). We also measured airborne ribavirin concentrations in the personal breathing zones of nurses. Ventilators and other administration units that were enclosed by an aerosol containment tent produced significantly lower airborne ribavirin exposures than administration units without a containment tent did (range, < 2.5 to 78 micrograms/m3). On the basis of this and other evaluations of airborne ribavirin concentrations, we recommend using aerosol containment systems with all types of ribavirin administration units except mechanical ventilators.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8882097     DOI: 10.1097/00043764-199603000-00010

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  5 in total

1.  Precautionary Practices of Respiratory Therapists and Other Health-Care Practitioners Who Administer Aerosolized Medications.

Authors:  Rebecca J Tsai; James M Boiano; Andrea L Steege; Marie H Sweeney
Journal:  Respir Care       Date:  2015-07-07       Impact factor: 2.258

2.  Occupational risk factors and asthma among health care professionals.

Authors:  George L Delclos; David Gimeno; Ahmed A Arif; Keith D Burau; Arch Carson; Christine Lusk; Thomas Stock; Elaine Symanski; Lawrence W Whitehead; Jan-Paul Zock; Fernando G Benavides; Josep M Antó
Journal:  Am J Respir Crit Care Med       Date:  2006-12-21       Impact factor: 21.405

Review 3.  Prevention and treatment recommendations for respiratory syncytial virus infection. Background and clinical experience 40 years after discovery.

Authors:  M G Ottolini; V G Hemming
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

Review 4.  Update in the treatment of non-influenza respiratory virus infection in solid organ transplant recipients.

Authors:  Shellee A Grim; Gail E Reid; Nina M Clark
Journal:  Expert Opin Pharmacother       Date:  2017-04-28       Impact factor: 3.889

5.  Antiviral agents against respiratory viruses.

Authors:  Cecile L Tremblay
Journal:  Clin Microbiol Newsl       Date:  2001-12-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.